Response to Article “Microfluidic Synthesis of miR-200c-3p Lipid Nanoparticles: Targeting ZEB2 to Alleviate Chondrocyte Damage in Osteoarthritis” [Letter]

We recently read with great interest the article "Microfluidic Synthesis of miR-200c-3p Lipid Nanoparticles: Targeting ZEB2 to Alleviate Chondrocyte Damage in Osteoarthritis" by Zheng et al, 1 published in your journal.This study presents an innovative approach to treating osteoarthritis (OA) using miR-200c-3p lipid nanoparticles synthesized via microfluidic technology to target ZEB2 and mitigate chondrocyte damage.The research successfully constructs a novel drug delivery system with Lipo-AgPEI-miR-200c-3p, which not only enhances the delivery efficiency of miR-200c-3p but also significantly reduces material cytotoxicity. 2This is crucial for the potential clinical application of miRNA in OA treatment.The study also confirms that miR-200c-3p targets ZEB2, regulating the inflammatory response, apoptosis, and matrix degradation of chondrocytes, revealing a key role in OA development and providing a new molecular target for therapy. 3owever, the study has some limitations.Firstly, it lacks in vivo model validation.While the in vitro results are promising, the therapeutic effects and safety of Lipo-AgPEI-miR-200c-3p need to be verified in animal models to better understand its potential in a more complex biological environment.Secondly, the research does not sufficiently address the long-term efficacy and safety of the nanoparticles.Long-term stability and potential side effects are critical for clinical translation, and further studies are needed to evaluate these aspects.Lastly, the study could benefit from a broader consideration of the diverse pathological mechanisms of OA, such as oxidative stress and cellular senescence, to provide a more comprehensive therapeutic strategy. 4n conclusion, the work by Zheng et al offers valuable insights into the development of nano-drug delivery systems for OA.However, to fully realize the clinical potential of Lipo-AgPEI-miR-200c-3p, future research should focus on in vivo efficacy and safety assessments, as well as a more comprehensive understanding of its impact on the multifaceted pathological processes of OA.Thank you for considering our comments.